TrialClinical and translational science2024

Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.

Philipp Badorrek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.